Today: 7 February 2026
Subscribe
Browse Category

Pharmaceutical Industry News 21 December 2025 - 24 December 2025

Merck (MRK) Stock After Hours Today: Shares Hit a New 52-Week High on Dec. 24, 2025 — What to Know Before U.S. Markets Reopen

Merck (MRK) Stock After Hours Today: Shares Hit a New 52-Week High on Dec. 24, 2025 — What to Know Before U.S. Markets Reopen

NEW YORK — December 24, 2025: Merck & Co., Inc. (NYSE: MRK) ended a holiday-shortened Christmas Eve session near $106.45, up about 1.3% on the day, and held close to those levels in thin after-hours trading. MarketBeat The move capped a strong late-December run for the pharmaceutical blue chip and came as the broader U.S. market pushed to fresh records in a “Santa rally” setup—an upbeat backdrop that helped lift several Dow components, including Merck. Reuters+1 Below is what investors and traders should know after the bell on 12/24/2025, and what to watch before the next U.S. cash-session open (note:
24 December 2025
·····
Edgewise Therapeutics Stock (EWTX) Jumps on EDG-7500 CIRRUS-HCM Update: Dec. 24, 2025 News, Analyst Forecasts, and Key Catalysts

Edgewise Therapeutics Stock (EWTX) Jumps on EDG-7500 CIRRUS-HCM Update: Dec. 24, 2025 News, Analyst Forecasts, and Key Catalysts

Edgewise Therapeutics, Inc. (NASDAQ: EWTX) stock surged in intraday trading on Wednesday, December 24, 2025, after the company released a fresh update on EDG-7500, its investigational therapy for hypertrophic cardiomyopathy (HCM). By late morning, shares were trading around $26.37—up roughly 21% versus the prior close—after swinging between about $21.30 and $27.05 on the day, with volume above 2.2 million shares. The move follows a company announcement that it has completed Parts B and C of its Phase 2 CIRRUS-HCM trial and reported favorable interim safety observations from Part D—an update that several market outlets characterized as a meaningful de-risking moment
24 December 2025
····
Merck (MRK) Stock After Hours Today (Dec. 23, 2025): Shares Slip Slightly After the Close as Investors Track TrumpRx Pricing Deal, FDA Fast-Track Vouchers, and Fresh Wall Street Targets

Merck (MRK) Stock After Hours Today (Dec. 23, 2025): Shares Slip Slightly After the Close as Investors Track TrumpRx Pricing Deal, FDA Fast-Track Vouchers, and Fresh Wall Street Targets

NEW YORK — Merck & Co., Inc. (NYSE: MRK) ended regular trading Tuesday, December 23, 2025, at $105.04, and eased modestly in after-hours trading to about $104.81 (down roughly 0.2%) as of early evening in New York. Google The move after the bell was small, but MRK’s two-day run has been anything but: the stock is coming off a sharp gain on Monday (Dec. 22) and is trading within reach of its 52-week high—a setup that often makes the next session more about “what’s next” than what just happened. StockAnalysis+1 Below is what investors and traders will want on their
24 December 2025
·····
Bristol-Myers Squibb (BMY) Stock News Today: Supreme Court Bid, Drug-Pricing Deals, Dividend Boost, and 2026 Forecasts (Dec. 23, 2025)

Bristol-Myers Squibb (BMY) Stock News Today: Supreme Court Bid, Drug-Pricing Deals, Dividend Boost, and 2026 Forecasts (Dec. 23, 2025)

Bristol-Myers Squibb Company (NYSE: BMY) stock is back in the spotlight on Tuesday, December 23, 2025, as investors weigh a fast-moving U.S. drug-pricing landscape, fresh legal headlines tied to Medicare negotiations, and new analyst commentary on competitive pressure in a key growth product category. At the same time, Bristol Myers is heading into 2026 with a higher dividend, a defined near-term calendar (including a February earnings date), and intensifying debates over whether the stock’s “value” profile is a bargain—or a reflection of policy risk and the post-patent “reset” that still hangs over Big Pharma. BMY stock price today (December 23,
23 December 2025
·····
Eli Lilly Stock (LLY) Today: Wegovy Pill Approval Raises the Stakes in GLP‑1s as Wall Street Forecasts Point to a High‑Expectation 2026

Eli Lilly Stock (LLY) Today: Wegovy Pill Approval Raises the Stakes in GLP‑1s as Wall Street Forecasts Point to a High‑Expectation 2026

December 23, 2025 — Eli Lilly and Company stock (NYSE: LLY) is holding near record territory as investors digest a fresh twist in the weight-loss drug race: the FDA has cleared Novo Nordisk’s first oral version of Wegovy, intensifying competition right as Lilly pushes its own once-daily pill candidate, orforglipron, toward a potential 2026 approval. As of 15:11 UTC on Tuesday, LLY traded around $1,077, slightly above the prior close, after moving between roughly $1,057 and $1,088 during the session. The backdrop is simple but powerful: the obesity market is expanding fast, and the “next chapter” is about convenience, supply,
23 December 2025
·····
Teva Pharmaceutical Industries (TEVA) Stock Hits Fresh Highs as S&P Upgrades Credit Rating and Analysts Lift Targets to $40

Teva Pharmaceutical Industries (TEVA) Stock Hits Fresh Highs as S&P Upgrades Credit Rating and Analysts Lift Targets to $40

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is back in the market spotlight on December 23, 2025, with its stock hovering near the top of its 52-week range as a pair of momentum-friendly headlines land at once: a credit rating upgrade from S&P Global Ratings and a fresh bull-case valuation reset from Piper Sandler. Teva shares traded around $31.21, with the session pushing as high as roughly $31.28—also the top of its reported 52-week range ($12.47–$31.28). The company’s market cap was listed around $36.4 billion. Investing.com For investors, the big question now isn’t simply “why is TEVA stock moving today?” It’s
23 December 2025
···
GSK Stock News Today (Dec. 23, 2025): Buyback Update, Director Buying, US Drug-Pricing Deal, and FDA Wins — What Analysts Forecast Next

GSK Stock News Today (Dec. 23, 2025): Buyback Update, Director Buying, US Drug-Pricing Deal, and FDA Wins — What Analysts Forecast Next

GSK plc stock is ending 2025 with a dense cluster of catalysts—some bullish, some complicated, and all very “big pharma in an election-year policy blender.” Early Tuesday (Dec. 23, 2025), GSK’s ADR (NYSE: GSK) traded around $48.59, essentially flat on the session. Yahoo FinanceBehind that quiet tape, the company has been filing fresh buyback disclosures, reporting director share purchases, and navigating new US drug-pricing agreements—while continuing to stack up regulatory wins across respiratory and infectious disease. Below is what’s driving the GSK stock narrative right now, and how the latest forecasts and analyst views frame the next leg. What’s new
23 December 2025
·····
Alnylam Pharmaceuticals (ALNY) Stock: Nasdaq-100 Entry, Amvuttra Momentum, Analyst Targets and Key Risks to Know Before the Dec. 22, 2025 Market Open

Alnylam Pharmaceuticals (ALNY) Stock: Nasdaq-100 Entry, Amvuttra Momentum, Analyst Targets and Key Risks to Know Before the Dec. 22, 2025 Market Open

Ahead of the U.S. stock market open on Monday, December 22, 2025, Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is stepping into a new spotlight—not just for biotech fundamentals, but also for a major index catalyst that can reshape short-term trading dynamics. As of the most recent close, ALNY last traded around $400.23, within a roughly $220–$500 52-week range. Below is what investors and traders typically want on their radar before the bell: the Nasdaq-100 inclusion effect, the latest regulatory and commercial momentum for Amvuttra, the most recent corporate/financial updates, and what Wall Street forecasts imply from here. What to know in
22 December 2025
·····
Amicus Therapeutics (FOLD) Stock Week Ahead: $14.50 BioMarin Buyout Puts the Deal Spread—and New Filings—Front and Center (Dec. 22–26, 2025)

Amicus Therapeutics (FOLD) Stock Week Ahead: $14.50 BioMarin Buyout Puts the Deal Spread—and New Filings—Front and Center (Dec. 22–26, 2025)

As of Sunday, December 21, 2025, Amicus Therapeutics, Inc. (NASDAQ: FOLD) is no longer trading like a “typical biotech story stock.” After BioMarin’s all-cash $14.50-per-share takeover agreement, FOLD has effectively become a deal-driven, merger-arbitrage name—meaning next week’s action is likely to hinge less on quarterly fundamentals and more on the probability, timing, and conditions of closing. SEC+1 FOLD last traded around $14.18 (near the offer price), reflecting how quickly the market repriced the shares after the announcement. Investors.com Below is the week-ahead playbook: the latest news as of 21.12.2025, what Wall Street is saying, and the specific catalysts that could
22 December 2025
······
Amgen (AMGN) Stock Week Ahead Forecast: Drug-Price Deal Fallout, Analyst Targets, and Year-End Catalysts to Watch (Dec. 22–26, 2025)

Amgen (AMGN) Stock Week Ahead Forecast: Drug-Price Deal Fallout, Analyst Targets, and Year-End Catalysts to Watch (Dec. 22–26, 2025)

Amgen Inc. (NASDAQ: AMGN) heads into the Christmas-shortened trading week with a fresh wave of policy headlines, a newly expanded FDA label win in rare disease, and a market still laser-focused on what comes next for its obesity pipeline. Shares last traded around $327.38, following a session that ranged roughly between $323 and $331—levels that now matter even more in holiday-thinned liquidity. This coming week is also structurally different for U.S. equities: the NYSE closes early at 1:00 p.m. ET on Wednesday, Dec. 24, 2025 and is closed on Thursday, Dec. 25, 2025. That reduced time window can amplify single
21 December 2025
·····
Amicus Therapeutics Stock (FOLD) News: BioMarin’s $14.50 Cash Buyout, Deal Timeline, and the Latest Forecasts (Dec. 21, 2025)

Amicus Therapeutics Stock (FOLD) News: BioMarin’s $14.50 Cash Buyout, Deal Timeline, and the Latest Forecasts (Dec. 21, 2025)

As of Sunday, December 21, 2025, Amicus Therapeutics, Inc. (NASDAQ: FOLD) has effectively shifted from a “biotech story stock” to a deal-driven stock. The reason is simple and decisive: BioMarin Pharmaceutical (NASDAQ: BMRN) agreed to acquire Amicus in an all-cash transaction priced at $14.50 per share, putting a hard cap on the near-term upside—unless a competing bid emerges. SEC+1 With U.S. markets closed for the weekend, the most recent close available is $14.18 (Dec. 19, 2025)—a roughly 30% one-day jump that pushed shares close to the deal price and turned the remaining gap into a classic merger-arbitrage spread. StockAnalysis Below
21 December 2025
······
Pfizer Stock (PFE) in Focus: 2026 Guidance, Drug-Price Deal Pressures, and Pipeline Catalysts Investors Are Watching

Pfizer Stock (PFE) in Focus: 2026 Guidance, Drug-Price Deal Pressures, and Pipeline Catalysts Investors Are Watching

Dec. 21, 2025 — Pfizer Inc. (NYSE: PFE) ends the week in the spotlight after management laid out a 2026 outlook that undershot some Wall Street expectations, while a string of pipeline updates, partnerships, and policy headlines reshaped the near-term narrative around the long-time pharma bellwether. Reuters+1 Pfizer stock last closed at $25.25 on Friday, Dec. 19, with investors weighing whether the company’s cost-cutting and deal-making can offset the twin headwinds of fading COVID-era revenue and a looming patent cliff. Yahoo Finance+1 Why Pfizer stock is moving: the 2026 forecast reset The biggest driver of this week’s debate is Pfizer’s
21 December 2025
·····
1 … 4 5 6 7 8 … 12

Stock Market Today

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop